Vericel Corporation (VCEL)Healthcare | Biotechnology | Burlington, United States | NasdaqGM
40.25 USD
-0.05
(-0.124%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 40.25 |
Hot Take ↕ | Oct. 10, 2026, 4:05 a.m. EDT
The recent earnings beat and raised guidance provide a necessary floor for the stock, yet the underlying business remains a high-risk biotech play with a massive valuation gap. The trailing P/E of 85x is extreme given the razor-thin operating margins (0.56%), implying the market is pricing in a perfect execution of future growth rather than current profitability. While the long-term trajectory shows a massive cumulative gain (+958%) driven by a decade-long expansion, the last two years have been volatile, with a recent 20% drop erasing prior gains. The short-term outlook is neutral; the statistical forecast model offers no directional edge, and the options market is skewed toward hedging downside risk rather than chasing upside momentum. Investors should view this as a speculative bet on a turnaround story rather than a stable compounder. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.086815 |
| MSTL | 0.087732 |
| AutoTheta | 0.088488 |
| AutoETS | 0.088748 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 39.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.188 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 25.168 |
| Revenue per Share | 6.037 |
| Market Cap | 2,061,066,240 |
| Trailing P/E | 85.64 |
| Forward P/E | 47.58 |
| Beta | 1.03 |
| Profit Margins | 7.91% |
| Website | https://www.vcel.com |
As of Oct. 10, 2026, 4:05 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume at strikes significantly below the current price (20, 25, 22.5), suggesting a fear of a sharp downside gap or a 'floor' test. Conversely, call activity is sparse and concentrated at near-term strikes (45, 55) with low open interest, indicating limited speculative capital betting on an immediate breakout despite the recent earnings beat.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.1982733 |
| Address1 | 25 Blue Sky Drive |
| All Time High | 1,590.0 |
| All Time Low | 1.69 |
| Ask | 52.78 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 552,620 |
| Average Daily Volume3 Month | 504,636 |
| Average Volume | 504,636 |
| Average Volume10Days | 552,620 |
| Beta | 1.025 |
| Bid | 39.62 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 7.231 |
| City | Burlington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.25 |
| Current Ratio | 5.039 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 40.31 |
| Day Low | 39.595 |
| Debt To Equity | 25.168 |
| Display Name | Vericel |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,414,600 |
| Earnings Call Timestamp Start | 1,785,414,600 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 31,154,000 |
| Ebitda Margins | 0.10170999 |
| Enterprise To Ebitda | 63.932 |
| Enterprise To Revenue | 6.503 |
| Enterprise Value | 1,991,741,184 |
| Eps Current Year | 0.516 |
| Eps Forward | 0.846 |
| Eps Trailing Twelve Months | 0.47 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 588 5554 |
| Fifty Day Average | 41.2082 |
| Fifty Day Average Change | -0.95819855 |
| Fifty Day Average Change Percent | -0.02325262 |
| Fifty Two Week Change Percent | 19.82733 |
| Fifty Two Week High | 49.32 |
| Fifty Two Week High Change | -9.07 |
| Fifty Two Week High Change Percent | -0.18390106 |
| Fifty Two Week Low | 28.95 |
| Fifty Two Week Low Change | 11.299999 |
| Fifty Two Week Low Change Percent | 0.3903281 |
| Fifty Two Week Range | 28.95 - 49.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 855,066,600,000 |
| Float Shares | 50,576,773 |
| Forward Eps | 0.846 |
| Forward P E | 47.57683 |
| Free Cashflow | 55,544,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 398 |
| Fullday Change | -0.049999237 |
| Fullday Change Percent | -0.12406759 |
| Fullday Price | 40.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.7456 |
| Gross Profits | 228,380,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0119 |
| Held Percent Institutions | 1.10448 |
| Implied Shares Outstanding | 51,206,614 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investors.aastrom.com/investors.cfm |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,381,881,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts. |
| Long Name | Vericel Corporation |
| Market | us_market |
| Market Cap | 2,061,066,240 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_24153 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 24,221,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,986,304,557 |
| Number Of Analyst Opinions | 7 |
| Open | 39.9 |
| Operating Cashflow | 69,670,000 |
| Operating Margins | 0.0056 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 617 588 5555 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 40.25 |
| Post Market Time | 1,792,008,068 |
| Previous Close | 40.3 |
| Price Eps Current Year | 78.00388 |
| Price Hint | 2 |
| Price To Book | 5.566312 |
| Price To Sales Trailing12 Months | 6.7288475 |
| Profit Margins | 0.07908 |
| Quick Ratio | 4.534 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.0499992 |
| Regular Market Change Percent | -0.124068 |
| Regular Market Day High | 40.31 |
| Regular Market Day Low | 39.595 |
| Regular Market Day Range | 39.595 - 40.31 |
| Regular Market Open | 39.9 |
| Regular Market Previous Close | 40.3 |
| Regular Market Price | 40.25 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 384,548 |
| Return On Assets | 0.02429 |
| Return On Equity | 0.07157 |
| Revenue Growth | 0.225 |
| Revenue Per Share | 6.037 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 51,206,614 |
| Shares Percent Shares Out | 0.1016 |
| Shares Short | 5,202,417 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,759,226 |
| Short Name | Vericel Corporation |
| Short Percent Of Float | 0.1309 |
| Short Ratio | 10.21 |
| Source Interval | 15 |
| State | MA |
| Symbol | VCEL |
| Target High Price | 72.0 |
| Target Low Price | 52.0 |
| Target Mean Price | 59.71429 |
| Target Median Price | 59.0 |
| Total Cash | 162,458,000 |
| Total Cash Per Share | 3.173 |
| Total Debt | 93,133,000 |
| Total Revenue | 306,303,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.47 |
| Trailing P E | 85.6383 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 38.4192 |
| Two Hundred Day Average Change | 1.8307991 |
| Two Hundred Day Average Change Percent | 0.04765323 |
| Type Disp | Equity |
| Volume | 384,548 |
| Website | https://www.vcel.com |
| Zip | 1,803 |